Ciprofloxacin hydrochloride-loaded glyceryl monostearate nanoparticle: Factorial design of Lutrol F68 and Phospholipon 90G

Journal of Microencapsulation

Volumn 29, Issue 4, 2012, Pages 331-343

  Shah, Malay ^a   Agrawal, Yadvendra ^a  

^a GUJARAT FORENSIC SCIENCES UNIVERSITY   (India)

Author keywords

Ciprofloxacin HCl; Design expert; Glyceryl monostearate nanoparticles; Lutrol F68; Phospholipon 90G; Solubility parameter

Indexed keywords

CIPROFLOXACIN; GLYCEROL STEARATE; PHOSPHATIDYLCHOLINE; POLOXAMER; SOLID LIPID NANOPARTICLE;

ARTICLE; DIFFUSION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; DRUG STORAGE; EVAPORATION; HYDROPHILICITY; PARTICLE SIZE; PHOTON CORRELATION SPECTROSCOPY; SCANNING ELECTRON MICROSCOPY; SURFACE CHARGE; ZETA POTENTIAL;

ANTI-INFECTIVE AGENTS; CIPROFLOXACIN; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; GLYCERIDES; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; NANOCAPSULES; NANOPARTICLES; PARTICLE SIZE; POLYETHYLENE GLYCOLS; SOLUBILITY; SURFACE PROPERTIES;

EID: 84861030382     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652048.2011.651498     Document Type: Article

References (53)

1. Ahlin P, Kristl J, Smid-Korbar J. Optimization of procedure parameters and physical stability of solid lipid nanoparticles in dispersions. Acta Pharm, 1998;48:259-67.
2. Ahmad H, Yaseen M. Application of a chemical group contribution technique for calculating solubility parameters of polymers. Polymer Eng Sci, 1979;19:858-63.
3. Banker GS, Rhodes CT, 2002. Modern pharmaceutics. New York: Informa HealthCare.
4. Barton AFM, 1991. CRC handbook of solubility parameters and other cohesion parameters. Florida: CRC.
5. Barton AFM. Applications of solubility parameters and other cohesion parameters in polymer science and technology. Pure Appl Chem, 1985;57:905-12.
6. Bordes C, Fréville V, Ruffin E, Marote P, Gauvrit JY, Briançon S, Lantéri P. Determination of poly(-caprolactone) solubility parameters: Application to solvent substitution in a microencapsulation process. Int J Pharm, 2010;383:236-43.
7. Cavalli R, Caputo O, Marengo E, Pattarino F, Gasco MR. The effects of components of microemulsions on both size and crystalline structure of solid lipid nanoparticles (SLN) containing a series of model molecules. Pharmazie, 1998;53:392-96.
8. Charoo NA, Kohli K, Ali A, Anwer A. Ophthalmic delivery of ciprofloxacin hydrochloride from different polymer formulations: in vitro and in vivo studies. Drug Dev Ind Pharm, 2003;29(2):215-21.
9. Chatzaeiaoannou TP, 1993. Quantitative calculations in pharmaceutical practice and research. New York: VCH Publishers.
10. Clausse M, 1983. Dielectric Properties of emulsions and related systems. In: Becher P, editor. Encyclopedia of emulsion technology. Vol. 1, New York: Marcel Dekker Inc., pp. 481-715.
11. Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Biopharm, 2001;13:123-33.
12. Dillena K, Vandervoorta J, Mooterb G, Verheydenb L, Ludwig A. Factorial design, physicochemical characterisation and activity of ciprofloxacin-PLGA nanoparticles. Int J Pharm, 2004;275:171-87.
13. Egger SF, Ruckhofer J, Alzner E, Hell M, Hitz W, Grabner G. In vitro susceptibilities to topical antibiotics of bacteria isolated from the surface of clinically symptomatic eyes. Ophthalmic Res, 2001;33:117-20.
14. Ghebremeskel AN, Vemavarapu C, Lodaya M. Use of surfactants as plasticizers in preparing solid dispersions of poorly soluble API: Selection of polymer-surfactant combinations using solubility parameters and testing the processability. Int J Pharm, 2007;328:119-29.
15. Gohel MC, Panchal MK, Jogani VV. Novel mathematical method for quantitative expression of deviation from the Higuchi model. AAPS PharmSciTech, 2000;1:43-8.
16. Hansen CM, 2007. Hansen solubility parameters: A user's handbook. Florida: CRC.
17. Heurtault B, Saulnier P, Pech B, Proust JE, Benoit JP. Physico-chemical stability of colloidal lipid particles. Biomaterials, 2003;24:4283-300.
18. Higuchi T. Mechanism of sustained action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci, 1963;52:1145-9.
19. Komatsu H, Kitajima A, Okada S. Pharmaceutical characterization of commercially available intravenous fat emulsions: estimation of average particle size, size distribution and surface potential using photon correlation spectroscopy. Chem Pharm Bull, 1995;43:1412-15.
20. Li X, Nies S, Kong J, Li N, Jue C, Pana W. A controlled release ocular delivery system for ibuprofen based on nanostructured lipid carriers. Int J Pharm, 2008;363:177-82.
21. Magdassi S, Siman-Tov A. Formation and stabilization of perfluorocarbon emulsions. Int J Pharm, 1990;59:69-72.
22. Mehnert W, Mäder K. Solid lipid nanoparticles: Production, characterization and applications. Adv Drug Deliv Rev, 2001;47:165-96.
23. Mishra GP, Bagui M, Tamboli V, Mitra AK. Recent applications of liposomes in ophthalmic drug delivery. J Drug Deliv, 2011;2011:1-14.
24. Morel S, Ugazio E, Cavalli R, Gasco MR. Thymopentin in solid lipid nanoparticles. Int J Pharm, 1996;132:259-61.
25. Muller RH. Cytotoxicity of magnetite-loaded polylactide, polylactide/ glycolide particles and solid lipid nanoparticles. Int J Pharm, 1996;138: 85-94.
26. Muller RH. Solid lipid nanoparticles: Phagocytic uptake, in vitro cytotoxicity and in vitro biodegradation. Pharm Ind, 1999;61:564-9.
27. Muller RH, Maaben S, Weyhers H, Mehnert W. Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407. J Drug Target, 1996;4:161-70.
28. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-A review of the state of the art. Eur J Pharm Biopharm, 2000;50:161-77.
29. Muller RH, Ruhl D, Runge S, Schulze-Forster K, Mehnert W. Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm Res, 1997;14:458-62.
30. Müller RH, Wallis K, Tröster S, Kreuter J. In vitro characterization of poly (methyl-methaerylate) nanoparticles and correlation to their in vivo fate. J Contr Release, 1992;20:237-46.
31. Olbrich C, Gessner A, Schroder W, Kayser O, Muller RH. Lipid-drug conjugate nanoparticles of the hydrophilic drug diminazene-Cytotoxicity testing and mouse serum adsorption. J Cont Release, 2004a;96:425-35.
32. Olbrich C, Muller RH, Tabatt K, Kayser O, Schulze C, Schade R. Stable biocompatible adjuvants: a new type of adjuvant based on solid lipid nanoparticles: a study on cytotoxicity, compatibility and efficacy in chicken. Altern Lab Anim, 2002;30:443-58.
33. Olbrich C, Scholer N, Tabatt K, Kayser O, Muller RH. Cytotoxicity studies of Dynasan 114 solid lipid nanoparticles (SLN) on RAW 264.7 macrophages-Impact of phagocytosis on viability and cytokine production. J Pharm Pharmacol, 2004b;56:883-91.
34. Pandita D, Ahuja A, Lather V, Dutta T, Velpandian T, Khar R. Development, characterization and in vitro assessement of stearylamine-based lipid nanoparticles of paclitaxel. Pharmazie, 2011;66:171-7.
35. Reithmeier H, Herrmann J, Gopferich A. Lipid microparticles as a parenteral controlled release device for peptides. J Contr Release, 2001;73:339-50.
36. Reza M, Quadir MA, Haider SS. Development of theophylline sustained release dosage form based on kollidon SR. Pak J Pharm Sci, 2002;15:63-70.
37. Roberts R, Rowe R. The solubility parameter and fractional polarity of microcrystalline cellulose as determined by mechanical measurement. Int J Pharm, 1993;99:157-64.
38. Schubert M, Muller-Goymann C. Characterisation of surface-modified solid lipid nanoparticles (SLN): Influence of lecithin and nonionic emulsifier. Eur J Pharm Biopharm, 2005;61:77-86.
39. Schubert MA, Harms M, Muller-Goymann CC. Structural investigations on lipid nanoparticles containing high amounts of lecithin. Eur J Pharm, 2006;27:226-36.
40. Schwarz C. Solid lipid nanoparticles (SLN) for controlled drug delivery II. Drug incorporation and physicochemical characterization. J Microencapsul, 1999;16:205-13.
41. Shi L, Li Z, Yu L, Jia H, Zheng L. Effects of surfactants and lipids on the preparation of solid lipid nanoparticles using double emulsion method. Journal of Disper Sci Tech, 2011;32: 254-9.
42. Sinha VR, Srivastava S, Goel H, Jindal V. Solid lipid nanoparticles (SLN'S)-Trends and implications in drug targeting. Int J Adv Pharmaceut Sci, 2010;1:212-38.
43. Swardrick J, 2007. Encyclopedia of pharmaceutical technology. New York: Informa Healthcare.
44. Trotta M, Debernardi F, Caputo O. Preparation of solid lipid nanoparticles by a solvent emulsification-diffusion technique. Int J Pharm, 2003;257:153-60.
45. van Krevelen DW, Hoftyzer P, 1976. Properties of polymers. New York: Elsevier Publishing Company.
46. Vaughan C. Using solubility parameters in cosmetics formulation. J Soc Cosmet Chem, 1985;36:319-33.
47. Verheyen S, Augustijns P, Kinget R, Van den Mooter G. Determination of partial solubility parameters of five benzodiazepines in individual solvents. Int J Pharm, 2001;228:199-207.
48. Wang Y, Deng Y, Mao S, Jin S, Wang J, Bi D. Characterization and body distribution of-elemene solid lipid nanoparticles (SLN). Drug Dev Ind Pharm, 2005;31:769-78.
49. Westesen K, Siekmann B. Investigation of the gel formation of phospholipid-stabilized solid lipid nanoparticles. Int J Pharm, 1997;151:35-45.
50. Wiacek AE. Electrokinetic properties of n-tetradecane/lecithin solution emulsions. Colloid Surface Physicochem Eng Aspect, 2007;293:20-7.
51. Zimmer A, Kreuter J. Microspheres and nanoparticles used in ocular delivery systems. Adv Drug Deliv Rev, 1995;16:61-73.
52. Yassin AEB, Anwer M, Mowafy HA, El-Bagory I, Bayomi M, Alsarra I. Optimization of 5-fluorouracil solid-lipid nanoparticles: A preliminary study to treat colon cancer. Int J Med Sci, 2010;7(6):398-408.
53. Zimmermann E, Müller RH. Electrolyte-and pH-stabilities of aqueous solid lipid nanoparticle (SLN (TM)) dispersions in artificial gastrointestinal media. Eur J Pharm Biopharm, 2001;52:203-10.